Please login to the form below

Not currently logged in
Email:
Password:

Amgen poaches J&J’s Ray Jordan for corporate affairs post

He joins on October, 1 with a strategic communications remit

Amgen has appointed Ray Jordan to fill the newly created position of senior vice president of corporate affairs.

He will join the US biotech on October, 1 from Johnson & Johnson, where he has served as communications leader with responsibility for corporate comms and public affairs since 2003.

Prior to joining J&J, Jordan was vice president of communications and information for Pfizer, where he held a range of positions over the course of 17 years.

He has also served as chair of PhRMA's public affairs section and, earlier in his career, as a reporter for a regional daily newspaper as well as holding positions with Bristol-Myers and business information company Dun & Bradstreet.

In his new role Jordan will be responsible for strategic communications across Amgen, including internal and external communications, issues management and philanthropy, and report directly to Robert Bradway, Amgen's president and CEO.

Bradway said: "We are very pleased to have Ray join Amgen. He is a strategic thinker and communicator with skills honed at two respected global health care companies.

“Ray's background in both business management and communication will serve Amgen well as we execute on our strategy to deliver results for both patients and shareholders."

12th September 2012

From: Marketing

Share

Tags


Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Atlantis Healthcare

Established in 1993, Atlantis Healthcare provides unique solutions to address the issues of treatment non-adherence and patient self-management....

Latest intelligence

The changing regulatory environment
Code of practice changes are encouraging transparency in pharma/HCP relationships...
Online Physician Communities
Study highlights value of internet for doctors in Eastern Europe
Electronic direct mail is proving popular as online access increases...
England’s clinical commissioning landscape
Who are the real masters in the new NHS?...